Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy  by Donida, Bruna et al.
Biochimica et Biophysica Acta 1852 (2015) 1012–1019
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isOxidative stress and inﬂammation in mucopolysaccharidosis type IVA
patients treated with enzyme replacement therapyBruna Donida a,d,⁎, Desirèe P. Marchetti b,d, Giovana B. Biancini b,d, Marion Deon a,d, Paula R. Manini c,
Helen T. da Rosa c, Dinara J. Moura c, Jenifer Safﬁ c, Fernanda Bender d, Maira G. Burin d, Adriana S. Coitinho e,
Roberto Giugliani d,f, Carmen Regla Vargas a,b,d,⁎
a Programa de Pós-Graduação em Ciências Farmacêuticas, UFRGS, Av. Ipiranga, 2752, CEP 90610-000 Porto Alegre, RS, Brazil
b Programa de Pós-Graduação em Ciências Biológicas, Bioquímica, UFRGS, Rua Ramiro Barcelos, 2600, CEP 90035-003 Porto Alegre, RS, Brazil
c Laboratório de Genética Toxicológica, Universidade Federal de Ciências de Saúde de Porto Alegre, UFCSPA, Rua Sarmento Leite, 245, CEP 90050–170 Porto Alegre, RS, Brazil
d Serviço de Genética Médica, HCPA, Rua Ramiro Barcelos, 2350, CEP 90035-003 Porto Alegre, RS, Brazil
e Programa de Pós-Graduação em Ciências Biológicas-Fisiologia, Universidade Federal do Rio Grande do Sul, UFRGS, Instituto de Ciências Básicas e da Saúde, Rua Sarmento Leite, 500,
CEP 90050-170 Porto Alegre, RS, Brazil
f Departamento de Genética, e Programa de Pós-Graduação em Genética e Biologia Molecular, Instituto de Biociências, UFRGS, Av. Bento Gonçalves, 9500, CEP 90650-001 Porto Alegre, RS, BrazilAbbreviations:8-OHdG, 8-hydroxy-2′-deoxyguanosin
nitrobenzoic acid); Endo III, endonuclease III; ELISA, enzy
acetylgalactosamine-6-sulfate sulfatase; GPx, glutathione p
born errors ofmetabolism; IL-6, interleukin 6; LSDs, lysoso
standard error of themean; SOD, superoxide dismutase; TB
⁎ Corresponding authors at: Serviço de Genética Médic
E-mail addresses: donida.bruna@gmail.com (B. Donida
(M. Deon), maninipaula@gmail.com (P.R. Manini), htdaro
bender.fernanda@gmail.com (F. Bender), mburin@hcpa.u
(C.R. Vargas).
http://dx.doi.org/10.1016/j.bbadis.2015.02.004
0925-4439/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 December 2014
Received in revised form 9 February 2015
Accepted 11 February 2015
Available online 19 February 2015
Keywords:
Mucopolysaccharidosis type IVA
Morquio A Syndrome
Oxidative stress
Glycosaminoglycan
InﬂammationMucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism due to the
deﬁcient activity of N-acetylgalactosamine-6-sulfate sulfatase that leads to accumulation of the keratan sulfate
and chondroitin 6-sulfate in body ﬂuids and in lysosomes. The pathophysiology of this lysosomal storage disor-
der is not completely understood. The aim of this study was to investigate oxidative stress parameters, pro-
inﬂammatory cytokine and GAG levels inMPS IVA patients. We analyzed urine and blood samples from patients
under ERT (n= 17) and healthy age-matched controls (n= 10–15). Patients presented a reduction of antioxi-
dant defense levels, assessed by a decrease in glutathione content and by an increase in superoxide dismutase
activity in erythrocytes. Concerning lipid and protein damage, it was veriﬁed increased urine isoprostanes and
di-tyrosine levels and decreased plasma sulfhydryl groups in MPS IVA patients compared to controls. MPS IVA
patients showed higher DNA damage than control group and this damage had an oxidative origin in both pyrim-
idine and purine bases. Interleukin 6 was increased in patients and presented an inverse correlation with GSH
levels, showing a possible link between inﬂammation and oxidative stress inMPS IVA disease. The data present-
ed suggest that pro-inﬂammatory and pro-oxidant states occur inMPS IVA patients evenunder ERT. Taking these
results into account, supplementation of antioxidants in combination with ERT can be a tentative therapeutic
approach with the purpose of improving the patient's quality of life. To the best of our knowledge, this is the
ﬁrst study relating MPS IVA patients with oxidative stress.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Mucopolysaccharidoses (MPSs) are a heterogeneous group of
inherited lysosomal storage disorders (LSDs) caused by deﬁciency of
the enzymes involved in the degradation of glycosaminoglycans
(GAGs). MPSs are classiﬁed into 11 syndromes according to the speciﬁce; CAT, catalase; Cr, creatinine;DI, dam
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The GALNS enzyme deﬁciency leads to the accumulation of GAGs and
subsequent cellular damage, mainly in connective tissues where
keratan sulfate is abundant, specially cartilage, cornea and heart valve
[3,4]. The main clinical manifestations of MPS IVA patients are: skeletal
dysplasia, restricted growth and short stature, joint hypermobility, val-
vular heart disease, pulmonary disease, corneal clouding, hearing loss,
and poorly formed teeth [5]. It was already described about 277 muta-
tions in the GALNS gene, and this extensive allelic heterogeneity is
consistent with the broad spectrum of phenotypes observed in MPS
IVA [6,7]. The characteristic signs and symptoms of this disease appear
at around two or three years of age. Phenotypic spectrum may range
from a more attenuated phenotype, with patients reaching the age of
70 years, to a more severe phenotype, where patients survive no more
than 20–30 years [5,8–10]. MPS IVA patients have no neurological im-
pairment, differently of many other MPSs and inborn errors of metabo-
lism (IEM) [11].
Diagnosis of MPS IVA is typically based on clinical examination,
skeletal radiographs, evaluation of the pattern of urinary GAGs and
measurement of the enzymatic activity of GALNS in white blood cells
or ﬁbroblasts [5,10,12]. Until recently, there was no effective therapy
for MPS IVA and treatment was palliative, focusing on management of
the multiple clinical symptoms [10,13]. The recent introduction of ERT
with recombinant human enzyme (elosulfase alfa), however, has raised
the possibility that the burden of GAGs storage can be reduced and that
the progressive tissue and organ damage associated with MPS IVA can
be slowed or even prevented. In a recent study,MPS IVA patients under-
going ERT showed improvements in 6-minute-walk test and a decrease
in keratan sulfate levels [14].
Oxidative stress may play an important role in the pathophysiology
of some IEM. Even though this relationship is not well elucidated, the
accumulation of toxic metabolites is considered the main responsible
for the increased generation of reactive species, which can react with
lipids, proteins, DNA and RNA [15–18]. Most studies linking oxidative
stress and MPS were performed in animal models. In this context, we
can mention the study developed by Villani et al. [19] that showed the
presence of oxidative stress even in the early stages of MPS IIIB, and an-
other work demonstrating an oxidative imbalance in an animal model
of MPS I [20]. Furthermore, a possible link between inﬂammation and
oxidative stress in MPS IIIA mice was reported by Arﬁ et al. [21]. In ani-
mal models of MPS VI and VII, it was veriﬁed an inﬂammation process
caused by intralysosomal accumulation of GAGs, which could trigger
the release of cytokines, chemokines, proteases and nitric oxide, culmi-
nating in apoptosis and consequent destruction of connective tissue
[22]. Ohmi et al. [23] showed microglia activation in mouse models of
MPS I and IIIB, and this activation is one possible explanation for the in-
volvement and occurrence of inﬂammatory processes alongwith oxida-
tive damage in various diseases. In mice with MPS IIIB, Di Domenico
et al. [24] demonstrated a signiﬁcant reduction in the expression of sev-
eral genes related to oxidative stress and inﬂammation, after sixmonths
of gene therapy, corroborating with the hypothesis that both processes
are involved in the pathogenesis of MPS IIIB.
With regard to research in patients, there are few reports relating
MPS with oxidative stress and inﬂammation. Pereira et al. [25] found
high lipid peroxidation levels in MPS I patients. Moreover, they showed
that ERTwas able to induce an increase of catalase (CAT) and a decrease
of superoxide dismutase (SOD) activities at speciﬁc times of treatment.
However, these enzymatic changes were not sufﬁcient to reduce lipid
peroxidation levels, suggesting an important role of oxidative stress in
the pathophysiology of MPS I, even during treatment. In a study with
MPS II patients, it was observed oxidative damage to proteins and lipids,
as well as increased CAT activity and decreased total antioxidant status
before treatmentwhen compared to controls. In these patients, until the
thirdmonth of the ERT, therewas a decrease in lipid peroxidation levels
and in protein damage, suggesting a possible involvement of oxidative
stress in the pathophysiology of MPS II and a protective role of therapy[26]. In addition, ERTwas capable to decreaseDNAdamage [27] and also
GAG levels in MPS II patients [28], what suggests that the decrease of
metabolites accumulation probably may be related to the improvement
of oxidative stress parameters. Nevertheless, patients with Fabry dis-
ease, another type of LSD, under ERT, presented high levels of oxidative
damage to proteins and lipids, accompanied by low antioxidant de-
fenses and high pro-inﬂammatory cytokines [29]. This study also
showed, in treated Fabry patients, a positive correlation between oxida-
tive stress, inﬂammation and the metabolites accumulated in this
disease.
Considering the involvement of oxidative stress and inﬂammation in
other MPSs and the lack of reports in this issue in MPS IVA, the aim of
this study was to evaluate oxidative damage to biomolecules, antioxi-
dant defenses, pro-inﬂammatory cytokine and GAG levels in patients
with Morquio A disease.
2. Materials and methods
2.1. Subjects
For this study it was collected blood and occasional urine samples
from 17 MPS IVA patients with ages varying between 6 and 36 years
(15.3 ± 8.9 years old, mean ± standard deviation). For the control
group we collected blood from 14 healthy individuals with ages ranging
between 10 and 28 years (24.0 ± 4.8 years old, mean ± standard devia-
tion) and for comet assay from 10 healthy individuals with ages varying
between 19 and 23 years (20.8 ± 1.5 years old, mean ± standard devia-
tion). Urinewas collected from 15 healthy individuals with ages between
7 and32 years (19.7±7.9 years old,mean±standarddeviation). AllMPS
IV A patients were receiving ERT treatment (elosulfase alfa—Vimizim®
2 mg/kg) every week by intravenous infusion, for about 32 weeks. At
themoment of diagnosis, patients presented the classic symptoms, usual-
ly including short stature, skeletal deformities (pectus carinatum and
genu valgum almost always present), limited ambulation, restrictive air-
way disease, heart valves problems and corneal clouding. Patients' data
were described in Table 1. Diagnosis was conﬁrmed by evaluation of
GAGs inurine (increased total content andpresence of increased amounts
of keratan sulfate) and measurement of GALNS in leucocytes (deﬁcient
activity) [10,30].
Informed consent was obtained from all participants. The study was
approved (number 13-0246) by The Ethics Committee of theHospital de
Clínicas de Porto Alegre (HCPA), RS, Brazil.
2.2. Sample collection and preparation
Occasional urine and heparinized blood sampleswere obtained from
patients immediately before the session of ERT. Urine samples were
collected in sterile ﬂask, aliquoted and frozen at−80 °C until analysis.
Samples were obtained from controls concomitantly. Whole blood was
centrifuged at 1000 ×g for 10 min and plasma was removed by aspira-
tion, aliquoted and frozen at−80 °C until biochemical determinations.
An aliquot of whole blood was separated for comet assay. Erythrocytes
were washed three times with cold saline solution (0.153mol/L sodium
chloride) and the lysates were prepared by addition of 1 mL of distilled
water to 100 μL of washed erythrocytes. The lysates were frozen at
−80 °C until determination of GSH and antioxidant enzymes activities.
For these determinations, the supernatant (after centrifugation at
13,500 ×g for 10 min) was diluted in order to contain approximately
0.5 mg/mL of protein.
2.3. Reduced glutathione (GSH) content in erythrocytes
In order to measure GSH levels, the main intracellular antioxidant,
lysates of erythrocytes were processed as described by Browne and
Armstrong [31] and the ﬂuorescence measured (λexcitation = 350 nm,
Table 1
Data of studied MPS IVA patients.
Patient Age
(years)
Gender Race and ethnicity Height
(cm)
Weight
(kg)
1 34.4 Female White-Hispanic/Latin 100 21.75
2 8.5 Male White-Hispanic/Latin 91.1 16.60
3 36.3 Female White-Hispanic/Latin 97.9 20.45
4 10.6 Female White-Hispanic/Latin 84.9 14.45
5 13.4 Male Mulatto-Hispanic/Latin 87.5 15.10
6 12.5 Male White-Hispanic/Latin 84.3 17.30
7 10.6 Female White-Hispanic/Latin 110 15.05
8 12.8 Female Mulatto-Hispanic/Latin 107 27.85
9 9.5 Male White-Hispanic/Latin 97.2 17.30
10 16.3 Male White-Hispanic/Latin 107.6 31.10
11 6.7 Female White-Hispanic/Latin 90.3 14.30
12 14.4 Male Black-Hispanic/Latin 96.4 21.00
13 9.5 Female Black-Hispanic/Latin 90.9 13.60
14 13.4 Female Mulatto-Hispanic/Latin 101.4 25.55
15 17.4 Male White-Hispanic/Latin 112 29.45
16 6.7 Male White-Hispanic/Latin 96.2 16.75
17 26.9 Female White-Hispanic/Latin 89.6 24.3
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GSH solutions. Results were expressed as nmol/mg protein.
2.4. Erythrocyte superoxide dismutase (SOD) activity
SOD activity was measured using the RANSOD® kit (Randox Lab,
Antrim, United Kingdom). The method is based on the formation of red
formazan from the reaction of 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
phenyltetrazolium chloride and superoxide radical, which is produced
by the incubation with the xanthine–xanthine oxidase reaction system.
The absorbance of the product is measured spectrophotometrically at
505 nm. One unit of SOD corresponds to a 50% inhibition of red formazan
formation. The speciﬁc activity of SOD was expressed as U/mg protein.
2.5. Erythrocyte glutathione peroxidase (GPx) activity
Erythrocyte GPx activity was measured by using a commercially
available kit (RANSEL®; Randox Lab). GPx catalyses the oxidation of
glutathione (GSH) to GSSG (oxidized glutathione). In the presence of
glutathione reductase (GR) and NADPH, the oxidized GSSG is converted
to the reduced form with a concomitant oxidation of NADPH to NADP.
The decrease in absorbance after 1 and 2 min at 340 nmwas measured
and results were expressed in U/mg protein.
2.6. Urine 15-F2t-isoprostane levels
15-F2t-isoprostane, a product of arachidonic acid metabolism and a
biomarker of lipid peroxidation, was measured by a competitive
enzyme-linked immunoassay (ELISA) (Oxford Biomed, EA 85), accord-
ing to the kit's instructions. First, the urine samples weremixedwith di-
lution buffer. In this assay, the 15-F2t-isoprostane in the urine samples
competes with the 15-F2t-isoprostane conjugated to horseradish per-
oxidase for the binding to a speciﬁc antibody ﬁxed on the microplate.
The concentration of 15-F2t-isoprostanewas determined spectrophoto-
metrically at 630 nm by the intensity of color developed after the addi-
tion of substrate. Results were expressed as picograms of isoprostanes
per mg of urinary creatinine (pg/mg Cr).
2.7. Urine di-tyrosine (di-Tyr) levels
In order to determine the levels of protein oxidation in urine, the in-
tensity of di-Tyr ﬂuorescence was measured according to the method
described by Kirschbaum [32]. For Di-tyr ﬂuorescence determination,
50 μL of thawed urine was added to 950 μL of 6 mol/L urea in
20 mmol/L sodium phosphate buffer pH 7.4. After 30 min, the concen-
trationwasmeasured using a ﬂuorometer (excitation 315 nm, emission410nm). Resultswere expressed asﬂuorescence units permgurine cre-
atinine (FU/mg Cr).2.8. Total plasmatic level of sulfhydryl groups
The plasmatic concentration of sulfhydryl groupswas determined as
described by Aksenov andMarkesbery [33]. Themethod is based on the
reduction of 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) by sulfhydryl
groups into a yellow derivative (TNB) whose absorption is measured
spectrophotometrically at 412 nm. The sulfhydryl content is inversely
correlated to oxidative damage to proteins. Results were reported as
μmol TNB/mg protein.2.9. Alkaline comet assay in leukocytes
The alkaline comet assay, that measures single and double DNA
strand breaks, was performed as described by Singh et al. [34] in accor-
dance with general guidelines for use of the comet assay [35]. Aliquots
of 100 μL from whole blood were suspended in agarose and spread
into a glass microscope slide pre-coated with agarose. Slides were
placed in ice-cold lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris
pH 10.0–10.5 with 10% DMSO and 1% Triton X-100) to remove cell pro-
teins and leaving DNA as “nucleoids”. After the lysis-buffer procedure,
the slides were covered with fresh buffer (300 mM NaOH and 1 mM
EDTA, pH N 13) for 15 min to allow DNA unwinding and then, electro-
phoresis was performed for 15 min (25 V; 300 mA; 0.9 V/cm). Slides
were neutralized with 0.4 M Tris (pH 7.5), washed in bi-distilled
water and stained using silver nitrate staining protocol [36]. After dry-
ing at room temperature overnight, the samples were analyzed using
an optical microscope. One hundred cells (50 cells from each of the
two replicate slides) were selected and analyzed. Cells were visually
scored according to tail length and received scores from 0 (no migra-
tion) to 4 (maximal migration). Therefore, the damage index (DI) was
calculated, ranged from 0 (completely undamaged: 100 cells × 0) to
400 (withmaximumdamage: 100 cells × 4) [35,37]. The slideswere an-
alyzed under blind conditions at least by two different individuals.
A digestion step with a bacterial repair enzyme was included in the
alkaline comet assay before electrophoresis, in accordance to Dizdaroglu
et al. [38]. The enzyme used was endonuclease III (Endo III, also known
as Nth) which converts oxidized pyrimidines (including thymine glycol
and uracil glycol) to strand breaks. It was obtained from New England
Biolabs (NEB, Ipswich, MA). After lysis, each slide was washed for
5 min in an enzyme buffer (40 mM HEPES-KOH, 1 M KCl, 5 mM EDTA,
2.5 mg/mL bovine serum albumin fraction V-BSA, and pH 8.0). The sus-
pension was added to the slide, covered with coverslip, and incubated
for 45 at 37 °C. Subsequent stepswere the same as in the alkaline version
of comet assay. DNA damage with Endo III was calculated as the score
obtained with enzyme minus the score without enzyme (basal).2.10. Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels
Urinary 8-OHdG levels, a product of DNA oxidative damage due to
the hydroxyl radical attack at the C8 position of deoxyguanosine, were
determined byHighly Sensitive 8-OHdG Check ELISA kit (JaICA, Fukuroi,
Japan). The 8-OHdG Check ELISA kit is a competitive in vitro enzyme-
linked immunosorbent assay for quantitative measurement of the oxi-
dative DNA adduct 8-hydroxy-2′-deoxyguanosine. This assay employs
amicroplatewith 96wells pre-coatedwith 8-OHdG, amonoclonal anti-
body speciﬁc for 8-OHdG (primary antibody), an HPR-conjugated anti-
body (secondary antibody) and colorimetric substrate detection whose
absorbance wasmeasured in an ELISA microwell reader at 450 nm. The
samples 8-OHdG concentrations (ng/mL) were calculated using a poly-
nomial equation from the relative absorbance of standard curve. After
creatinine correction, the results were expressed as ng/mg Cr.
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Plasma IL-6 was measured by commercial kit Human IL-6 ELISAPRO
(Mabtech AB, Sweden). The assay utilizes ELISA strip plates pre-coated
with a capture monoclonal antibody (mAb), to which samples were
added. Captured cytokine was detected by adding a biotinylated mAb
followed by streptavidin–horseradish peroxidase. The addition of the
enzyme substrate TMB results in a colored substrate product. The
color intensity is directly proportional to the concentration of cytokine
in the sample, which is determined by comparisonwith a serial dilution
of recombinant cytokine standard analyzed in parallel. The results were
expressed as pg/mL.
2.12. Urinary glycosaminoglycans (GAGs)
The measurement of urinary GAGs was performed according to the
technique described by de Jong et al. [30]. The technique principle is
based on formation of a complex between sulfated GAGs present in
urine with stain 1,9-dimethylmethylene blue (DMB). This complex
can be detected in a spectrophotometer at 520 nm. The results were
expressed in μg GAGs/mg Cr.
2.13. Urinary creatinine (Cr)
Creatinine was determined using Creatinine K kit of Labtest®
(Labtest Diagnóstica, Lagoa Santa, MG, Brazil), by reaction with picric
acid under alkaline conditions, producing an orange color whose absor-
bance was determined in a spectrophotometer at 492 nm. Results were
expressed as mg Cr/dL.
2.14. Protein determination
Plasma and erythrocyte protein concentrations were determined,
respectively, by Biuret method — using the commercial kit of Labtest®
(Labtest Diagnóstica, Lagoa Santa, MG, Brazil) — and by the method of
Lowry et al. [39].
2.15. Statistical analysis
All results were expressed as mean ± standard error of the mean
(SEM). Normal distribution was tested by the Shapiro–Wilk test.
Logarithmic (log) transformationwas done in data not normally distrib-
uted in order to transform them in parametric. Unpaired Student's t test
was used for all comparisons between the two groups. Correlations
between parameters were performed by Pearson's correlation test.
Differences were considered signiﬁcant when p b 0.05. Analyses were
performed by using the Statistical Package for the Social Sciences
(SPSS Inc., Chicago, IL, USA— SPSS version 19.0) software, and graphics
were constructed in GraphPad Prism (GraphPad Software Inc., San
Diego, CA, USA — version 5.0) software.
3. Results
3.1. Antioxidant defenses
The concentration of erythrocyte GSH, the main non-enzymatic an-
tioxidant in cells, was signiﬁcantly reduced in MPS IVA patients
(0.060 ± 0.004 nmol/mg protein) when compared to control group
(0.079 ± 0.006 nmol/mg protein) (p b 0.05) (Fig. 1A). The SOD activity
was signiﬁcantly increased in patients (5.75 ± 0.31 U/mg protein)
when compared to controls (4.45 ± 0.38 U/mg protein) (p b 0.05)
(Fig. 1B), while there was no signiﬁcant difference in GPx activity be-
tween patients (0.11 ± 0.006 U/mg protein) and controls (0.099 ±
0.006 U/mg protein) (p N 0.05) (Fig. 1C). All data were expressed as
the mean ± SEM.3.2. Oxidative damage to biomolecules
Results showed that MPS IVA patients had increased levels of oxida-
tive damage to lipids [urine isoprostanes levels (1233.6 ± 66.6 pg/mg
Cr) (Fig. 2A)] (p b 0.05), proteins [urine di-Tyr (16,523.6 ± 917.4 FU/mg
Cr) (Fig. 2B) and plasma sulfhydryl groups (30.37 ± 0.86 μmol TNB/mg
protein) (Fig. 2C)] (p b 0.01) when compared to controls (926 ±
93 pg/mg Cr; 11,586.3 ± 1336.4 FU/mg Cr, 41.22 ± 0.88 μmol TNB/mg
protein, respectively). In addition, MPS IVA patients showed signiﬁcant
increase in basal DNA damage (98.63 ± 5.07 arbitrary units) when com-
pared to controls (31.5 ± 3.79 arbitrary units) (p b 0.01) (Fig. 2D). After
Endo III enzyme treatment (that indicates pyrimidines bases damage),
MPS IVA patients also showed an increased DNA damage (75.38 ± 5.84
in patients versus 30.67 ± 9.58 arbitrary units in controls) (p b 0.01)
(Fig. 2E). The urinary excretion of 8-OHdG (biomarker of purine bases ox-
idative damage) was signiﬁcantly higher in patients (9.25 ± 0.82 ng/mg
Cr) when compared to controls (6.1 ± 0.54 ng/mg Cr) (p b 0.05)
(Fig. 2F). All data were expressed as the mean ± SEM.
3.3. Pro-inﬂammatory cytokine
The plasmatic IL-6 (Fig. 3) was increased in MPS IVA patients
(30.99 ± 4.53 pg/ml) when compared to controls (11.5 ± 0.33 pg/ml)
(p b 0.01). The data were expressed as the mean ± SEM.
3.4. Correlation between oxidative stress and pro-inﬂammatory cytokine
Erythrocytes GSH levels were inversely correlated with the plasma
IL-6 levels (Fig. 4) in MPS IVA patients (r=−0.848 p b 0.05).
3.5. GAG levels
Results showed that MPS IVA patients presented signiﬁcant higher
levels of urinary GAGs (2 ± 0.02 μg/mg Cr) when compared to controls
(1.57±0.07 μg/mgCr) (p b 0.01), despite they are receivingweekly ERT
for about 8 months (Fig. 5). The data were expressed as the mean ±
SEM and the values were reported in logarithmic scale.
4. Discussion
The primary biological consequence in LSDs is the increase in size
and number of the lysosomes, in an attempt to retain the growing con-
centration of undegradedmacromolecules, due to enzymatic deﬁciency.
However, the biochemical and cellular mechanisms by which this
intralysosomal accumulation leads to cell and tissue dysfunction remain
not completely clear [40]. Reactive species are formed and degraded
during normal aerobic metabolism in cells at physiological concentra-
tions and are required for the proper functioning of the body. However,
uncontrolled production of reactive species results in oxidative damage
to biomolecules, altering their function and even causing diseases [41].
The involvement of reactive species is described inmore than a hun-
dred human diseases, including some IEM [15–18,26–28,42]. Although
the relation between oxidative stress and IEM pathophysiology is not
well elucidated, the accumulation of toxic metabolites is appointed as
the main reason for the increase of free radicals formation [15–18]. De-
spite the fact that many studies relating oxidative damage to IEM exist,
there are few studies on LSDs, especially MPS. It is known that in this
diseases group, the imbalance between formation and removal of reac-
tive species might be even more important due to the lysosomal over-
load [20,25]. Lysosomes are very susceptible to oxidative stress and
destabilization of its membranes can result in release of hydrolases
and metabolites accumulated in cytosol causing apoptosis or necrosis.
Furthermore, the liberation of lysosomal contents can inducemitochon-
drial damage with secondary enhanced production of superoxide radi-
cals (O2•−) and hydrogen peroxide (H2O2), suggesting that lysosomal
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Fig. 1. Antioxidant defenses [reduced glutathione in erythrocytes—GSH (A), superoxide dismutase in erythrocytes—SOD (B), glutathione peroxidase in erythrocytes—GPx (C)] inMPS IVA
patients under ERT (n= 10–11) and controls (n= 10–13). Data represent mean ± SEM. *p b 0.05 (Student's t test for unpaired samples) compared to the control group.
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[43–46].
Recent studies of our group showed evidence that oxidative stress
may be involved in the pathophysiology of MPS II, and that ERT
protected against lipid, protein and DNA damage in these patients [26,
27]. Furthermore, another study carried out by our group veriﬁed that
patients with Fabry disease presented oxidative damage to proteins
and lipids, low antioxidant defenses and high pro-inﬂammatory cyto-
kine levels, even under ERT [29].
Considering this scenario, the aim of this study was to evaluate oxi-
dative stress parameters and inﬂammation biomarkers in MPS IVA
patients under ERT in order to better understand themechanisms relat-
ed to the pathophysiology of this complex syndrome.
It is widely established that several reactive oxygen species react
with membrane lipids (altering cell membrane ﬂuidity), proteins
(giving rise to carbonyl group formation into side-chains, reducing sulf-
hydryl groups of susceptible amino acids) and DNA (for example caus-
ing mutations) [41,47]. In our study we found decreased levels of
antioxidant defenses (erythrocyte GSH content) in MPS IVA patients
when compared to controls. The low GSH content implies a higher sus-
ceptibility to oxidative damage because GSH is themost important non-
enzymatic antioxidant, being preferentially oxidized by reactive species
and then preserving more important biomolecules [48]. On the other
hand, we observed high SOD activity in MPS IVA patients, showing,
probably, a response of the body to the increase of reactive species.
However, the high SOD activity is not accompanied by an increase of
GPx activity, which would be required for the degradation of H2O2
formed by the reaction of SOD. Thus, the H2O2 remains free and, by
Fenton reaction in the presence of Fe2+, yields the highly toxic hydroxyl
radical (OH•). This radical attacks all types of biomolecules around it,
being extremely dangerous to the cell [48]. Then, increased activity of
SOD could be deleterious and the balance between SOD and the
peroxide-removing enzymes like GPx may imply on redox status [49].
Hence, the low GSH content and the high SOD activity presented by
MPS IVA patients probably contribute to the oxidative stress process.
Conﬁrming our results, an increase of SOD activity in different organswas already veriﬁed in animalmodels ofMPS I and, probably, contribut-
ed to oxidative imbalance found in this model [20]. Regarding GSH, Arﬁ
et al. [21] veriﬁed a strongly lower ratio of GSH over the oxidized deriv-
ative (GSSG) in MPS IIIA mouse model when compared to normal
controls. Furthermore, aspirin treatment completely normalizes GSH
values, indicating a possible link between inﬂammation and oxidative
stress in this disease [21].
With respect to oxidative damage in biomolecules, we found in-
creased urine isoprostane levels in MPS IVA patients when compared
to controls. Isoprostanes are products derived from the free radical-
catalyzed peroxidation of arachdonic acid, independent of the cyclooxy-
genase enzyme. The continued oxidation and fragmentation of fatty acid
side chains can produce aldehydes like isoprostanes, malondialdehyde
(MDA) and 4-hydroxynonenal (formed from peroxidation of linolenic,
arachidonic or docosahexaenoic acids). These aldehydesmay cause rup-
ture of lysosomal (and other organelles) membrane and can bind to
membrane proteins, inactivating enzymes and receptors and even at-
tack DNA, forming mutagenic lesions [48,50]. Thus, the increased
isoprostane levels veriﬁed inMPS IVApatients could be a result of the ly-
sosome destabilization and also may be acting in the maintenance of
chain reactionswith othermolecules. Corroboratingwith these ﬁndings,
MPS I patients under ERT also showed damage to lipids,measured by in-
creased TBARS (thiobarbituric acid reactive substances) levels [25].
However, MPS II patients under ERT presented decrease of MDA when
compared to patients without treatment [26].
In this study, we also observed increased levels of di-Tyr in urine and
decreased levels of sulfhydryl groups in plasma of MPS IVA patients
when compared to controls. Sulfhydryl groups can be reversibly oxi-
dized by reactive species, suggesting that they represent a potential an-
tioxidant, acting in cellular defense against oxidative stress [49]. Since
two-thirds of sulfhydryl groups are bonded to proteins, a reduction of
these groups also characterizes a protein oxidation [51–53]. The
increase of urine di-Tyr levels reinforces protein oxidation found in
MPS IVA patients, since di-Tyr is formed by the oxidation of adjacent
protein tyrosine residues leading to the formation of a highly stable
inter-phenolic bond that does not undergo further metabolism [54].
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Fig. 2. Damage to lipids [isoprostanes in urine (A)], proteins [di-tyrosine in urine—di-Tyr (B), sulfhydryl groups in plasma—SH (C)] and DNA [basal DNA damage in leukocytes (D);
DNA damage with Endo III in leukocytes (E); 8-hydroxy-2′-deoxyguanosine in urine—8-OHdG (G)] in MPS IVA patients under ERT (n= 7–13) and controls (n= 6–13). Data represent
mean ± SEM. *p b 0.05, **p b 0.01 (Student's t test for unpaired samples) compared to the control group.
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test for unpaired samples) compared to the control group.
1017B. Donida et al. / Biochimica et Biophysica Acta 1852 (2015) 1012–1019Oxidative damage to proteins was also observed in animal models of
MPS I [20] and in MPS II patients [26]. During the ﬁrst three months of
treatment, the ERT therapy was able to increase sulfhydryl levels.
However, after three months, the sulfhydryl groups returned to the
values presented before treatment [26].
DNA damage has been associated with various pathologies, includ-
ing some IEM [17,27,55]. In this work, we investigated DNA damage in
MPS IVA patients under ERT by comet assay (single-cell electrophore-
sis), which is a widely used method, extremely sensitive for DNA dam-
age, inexpensive and quick [56]. In order to investigate themechanisms
underlyingDNAdamage, we assessedDNA repair using Endo III enzyme
which recognizes oxidized pyrimidines bases and converts them into
breaks reﬂected in comet tail [57]. Our results showed higher DNAdam-
age levels inMPS IVA patientswhen compared to control group and this
damage has an oxidative origin in pyrimidines bases. DNA damage was
also observed in a study with MPS II patients and in this study ERT was
able to decrease, but not reverse the levels of DNA damage [27]. For a
more accurate comparison with the data reported by Filippon et al.
[27] an investigation of this parameter in MPS IVA patients at diagnosis
Fig. 4. Correlation between GSH in erythrocytes and IL-6 in plasma of MPS IVA patients
under ERT (Pearson's correlation).
1018 B. Donida et al. / Biochimica et Biophysica Acta 1852 (2015) 1012–1019is necessary. The product of guanosine oxidation (purine base), 8-
OHdG, is formed by attack of reactive oxygen species in nuclear andmi-
tochondrial DNA [41]. The oxidized DNA is continuously repaired and
the injured nucleoside is excreted into the bloodstream and urine [58].
Phenylketonuric patients with uncontrolled diet, presented high 8-
OHdG levels in serum and this oxidative damage to DNA may be in-
duced by the high phenylalanine levels and the low total antioxidant
status veriﬁed in the plasma of these patients [59]. Our results are in
agreement with the above ﬁndings, since MPS IVA patients had higher
urinary excretion of 8-OHdG than control group. Combining this result
to those obtained by enzymatic comet assay, we can presume that the
MPS IVA patients exhibit oxidative damage to purine and pyrimidine
bases.
In order to investigate the mechanisms underlying inﬂammation,
we assessed IL-6 inﬂammatory cytokine. MPS IVA patients showed in-
creased plasma IL-6 levels compared to controls. This result provides ev-
idence that the pro-inﬂammatory state occurs in these patients. There
are few studies about inﬂammatory mediators in MPSs and most of
them were performed in animal models. These studies indicated a
high expression of inﬂammatory molecules and cytokines secondary
to the accumulation of GAGs in MPS IIIB, VI and VII [19,22,60]. In our
work, we also observed an inverse correlation between GSH and IL-6.
These data may suggest that the inﬂammatory process is associated toCo
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Fig. 5. Glycosaminoglycan (GAG) urinary levels in MPS IVA patients under ERT (n= 12)
and controls (n = 13). Data represent mean ± SEM. **p b 0.01 (Student's t test for un-
paired samples) compared to the control group.oxidative state in MPS IVA patients and is consistent with studies in-
volving animal model of MPS I, IIIA and IIIB [21,23,24].
Considering that GAG urinary levels in our study were still high in
patients compared to the control group,we propose that GAGs are relat-
ed, at least in part, with the oxidative damage found in MPS IVA pa-
tients. The present results for MPS IVA patients are in agreement with
those found in treated Fabry patients, once they also showed high
lipid and protein oxidative damage, decreased antioxidant defenses
and increased inﬂammatory biomarkers [29].
To the best of our knowledge, this is the ﬁrst study that describes the
increase of oxidative damage to biomolecules in MPS IVA patients.
Possibly, these data may provide new targets to future therapeutic
strategies in order to improve the life quality of MPS IVA patients.
Further researches and clinical trials are needed to reveal how safe
and effective would be the supplementation of antioxidants in combi-
nation with ERT in MPS IVA disease.
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